TL;DR: The Tirzepatide + Cagrilintide stack pairs a dual GIP/GLP-1 incretin agonist with a long-acting amylin analogue — two non-overlapping pathways that compound rather than compete. The protocol is the most evidence-grounded peptide combination in the modern weight-management research literature, modelled on the CagriSema phase-2/3 program. Expect ~25–27% body-weight loss in trial-style protocols, with manageable side effects.
TL;DR — quick comparison table
| Dimension | Tirzepatide alone | Tirzepatide + Cagrilintide stack |
|---|---|---|
| Receptor pathways | GIP + GLP-1 | GIP + GLP-1 + Amylin |
| Peak weight loss (modeled) | ~22.5% | ~25–27% |
| Trial reference | SURMOUNT-1 | CagriSema phase 2 (analog stack) |
| Total weekly dose at peak | 15 mg Tirz | 10 mg Tirz + 2.4 mg Cagri |
| Common side effects | Nausea, mild GI | Nausea (mild-moderate), injection-site reactions |
| Noki Labs cycle cost (12 wk) | ~₱16,800 | ~₱25,600 |
| Best for | First-time customers | Plateau-breakers, advanced protocols |
How the stack works (the science)
Tirzepatide: dual incretin agonism
Tirzepatide simultaneously activates GIP and GLP-1 receptors, amplifying post-meal insulin response, slowing gastric emptying, and dampening hypothalamic appetite drive. The dual incretin mechanism is what gives Tirzepatide its industry-leading mono-efficacy.
Cagrilintide: amylin layer with no incretin overlap
Cagrilintide is a long-acting amylin analogue that activates amylin and calcitonin receptors. Amylin signaling is mechanistically independent of GIP/GLP-1 — it works on satiety, gastric emptying, and post-meal glucagon suppression through entirely separate downstream cascades. That's why stacking it adds effect rather than diminishing returns.
Why two pathways beat one cranked-up pathway
Pushing Tirzepatide from 10 mg to 15 mg gains roughly 2 percentage points of weight loss while meaningfully increasing GI side effects. Layering Cagrilintide at 10 mg Tirzepatide gains ~3–5 percentage points with a much smaller GI hit — because the new effect comes from a fresh, untouched receptor system.
Clinical evidence — head to head
The cleanest evidence base is the CagriSema program (cagrilintide + semaglutide), which serves as a near-direct analog: Frias et al., Lancet 2023 — 15.6% weight loss at 32 weeks, vs 5.1% for cagri-mono and 8.1% for sema-mono. Substituting Tirzepatide for semaglutide raises the floor: SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed Tirzepatide alone reached 20.9% at 72 weeks. The Tirz+Cagri stack benefits from both signals: a stronger incretin base and an additive amylin layer.
The protocol (12-week titrated structure)
- Weeks 1–4: Tirzepatide 2.5 mg weekly. Cagrilintide held off. Establish GI tolerance.
- Weeks 5–8: Tirzepatide 5 mg weekly + Cagrilintide 0.3 mg weekly (different injection day).
- Weeks 9–12: Tirzepatide 7.5–10 mg weekly + Cagrilintide titrated 0.6 → 1.2 mg.
- Weeks 13–16 (extended protocols): Tirzepatide 10 mg + Cagrilintide 2.4 mg — ceiling for most individuals.
Inject on different days to spread GI load. Refrigerated reconstituted vials remain stable for ~28 days at 2–8°C.
Cost in the Philippines
Reference market: Atlas Compounds Retatrutide ~₱7,899/vial; MedsGo Tirzepatide ~₱5,985/vial. Noki Labs sits significantly below both:
| Item | Noki Labs unit | Total over 16 weeks |
|---|---|---|
| Tirzepatide 10 mg | ~₱2,800 | ~₱19,600 |
| Cagrilintide 10 mg | ₱2,200 | ~₱8,800 |
| Stack total | — | ~₱28,400 |
Apply BULK20 on stack orders over ₱15,000 for 20% off, or CLINIC15 on ₱10k+ orders.
Side effects — what's different on the stack
The stack does not double GI burden. Tirzepatide produces the dominant nausea signal during weeks 2–8; Cagrilintide adds mild incremental nausea at top dose plus occasional injection-site redness. The combined cardiovascular signal is essentially the Tirzepatide profile alone — Cagrilintide does not add HR or BP signal.
Who should run this stack
Plateau-breakers
If a Tirzepatide-only protocol has plateaued past week 16, layering Cagrilintide is the most evidence-supported next step.
Maximum-efficacy customers
For modeling near-bariatric weight reduction in individuals, this stack approaches the modeled ceiling of injectable peptide protocols.
GI-tolerant customers
This stack is not for first-time GLP-1 users. Establish Tirzepatide tolerance first.
Where to buy in the Philippines
- Tirzepatide: /products/tirzepatide
- Cagrilintide: /products/cagrilintide
Browse the full weight-management collection. Read the dedicated pillars at /pages/tirzepatide-philippines and /pages/cagrilintide-philippines. Compare the standalone heads at /pages/tirzepatide-vs-cagrilintide. Manila customers, see /pages/peptide-supplier-manila.
FAQ
Q: Can I start both peptides on day 1? Not recommended. Establish Tirzepatide GI tolerance for ~4 weeks first, then layer Cagrilintide.
Q: What's the highest practical Tirzepatide dose on the stack? 10 mg is the typical research ceiling on this stack — you don't need 15 mg if Cagrilintide is doing the additive work.
Q: Same syringe? No. Reconstitute and inject separately.
Q: Do they peak together? Both have ~5–7 day half-lives, so weekly dosing produces overlapping steady-state coverage.
Q: How long is a typical cycle? 16–24 weeks for full titrated protocols.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ